Status:

COMPLETED

Trial of Imatinib (Gleevec®) in Selected Patients With Metastatic Melanoma

Lead Sponsor:

Peking University

Collaborating Sponsors:

Novartis

Conditions:

Metastatic Melanoma

Eligibility:

All Genders

18-85 years

Phase:

PHASE2

Brief Summary

This study is a single-armed, open-label, single-center phase II trial of signal transduction inhibitor number 571 (STI-571) systemic therapy in selective patients with metastatic melanoma, and aims t...

Detailed Description

Only patients who meet the inclusion and exclusion criteria will be enrolled. The estimated recruitment duration is 1 year. Imatinib will be given in the dose of 400 mg orally each day unless disease ...

Eligibility Criteria

Inclusion

  • Histologically confirmed melanoma with metastases and has no received any systemic treatment within 1 month
  • Evidence of mutations and/or copy number increases of KIT with laboratory examination documented from either primary or metastatic tumor site
  • ECOG performance status 0, 1, or 2
  • Estimated life expectancy of 6 months or greater
  • Age 18 years or older, male of female
  • At least one measurable site of disease
  • Adequate organ function
  • Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures

Exclusion

  • Melanoma from primary sites other than acral or mucosal melanoma
  • Received systemic anti-cancer therapy within 1 month before enrollment for metastatic disease
  • Diagnosis of any second malignancy within the last 5 years, except for adequately treated basal cell carcinoma, squamous cell skin cancer, or in situ cervical cancer
  • Severe and/or uncontrolled concomitant medical diseases
  • pregnant or childbreeding women
  • Known hypersensitivity to imatinib
  • Current treatment on another clinical trial

Key Trial Info

Start Date :

December 1 2008

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

January 1 2011

Estimated Enrollment :

1 Patients enrolled

Trial Details

Trial ID

NCT00881049

Start Date

December 1 2008

End Date

January 1 2011

Last Update

January 17 2011

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Beijing Cancer Hospital

Beijing, Bejing, China, 10036